APEIRON Capital’s Summit Therapeutics SMMT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-961,866
Closed -$14M – 12
2026
Q2
$14M Sell
961,866
-347,275
-27% -$6.16M 9% 5
2026
Q1
$24.8M Sell
1,309,141
-100
-0% -$1.62K 23.21% 2
2025
Q4
$22.9M Sell
1,309,241
-1,700
-0.1% -$32K 26.48% 2
2025
Q3
$27.1M Buy
1,310,941
+110,000
+9% +$2.67M 12.87% 3
2025
Q2
$23.2M Buy
+1,200,941
New +$27.4M 21.87% 3

Other funds holding SMMT

APEIRON Capital's SMMT Position: Q3 2026 in Review

APEIRON Capital sold out of Summit Therapeutics (SMMT) in Q3 2026, closing a stake of 961,866 shares — an estimated $14M sold.

APEIRON Capital first reported a position in SMMT in Q2 2025 and held it in 5 quarters. The position peaked at $27.1M in Q3 2025. 211 funds tracked by Wall St. Rank hold SMMT as of Q3 2026.

  • APEIRON Capital reported no remaining Summit Therapeutics position as of Q3 2026 after selling out during the quarter.
  • APEIRON Capital sold 961,866 Summit Therapeutics shares in Q3 2026, an estimated $14M.
  • APEIRON Capital first reported a position in Summit Therapeutics in Q2 2025 and held it in 5 quarters.
  • APEIRON Capital's Summit Therapeutics position peaked at $27.1M in Q3 2025.
  • 211 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2026.

Based on APEIRON Capital's 13F filing for Q3 2026, filed 4 Nov 2026.